Drug Profile
Research programme: asparaginase-based therapeutics - Jazz Pharmaceuticals
Alternative Names: PASylated asparaginase; Recombinant crisantaspase - Jazz PharmaceuticalsLatest Information Update: 11 Mar 2024
Price :
$50
*
At a glance
- Originator Jazz Pharmaceuticals Inc
- Class Amidohydrolases; Antineoplastics; Enzymes
- Mechanism of Action Asparagine modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Haematological disorders; Precursor cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 08 Mar 2024 Preclinical development is ongoing in Precursor-cell-lymphoblastic-leukaemia-lymphoma and Haematological-disorders in USA (Jazz Pharmaceuticals SEC filing, Form 10-K, March 2024)
- 28 Aug 2021 No recent reports of development identified for preclinical development in Precursor-cell-lymphoblastic-leukaemia-lymphoma in USA
- 28 Jul 2021 No recent reports of development identified for preclinical development in Haematological-disorders in USA